Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -38.41% is 49% above its 5-year average of -75.66%, near the high end of its 5-year range (-110.41%–-19.76%).
54.74% above its 12-month average of -84.87%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.60%.
RETURN ON ASSETS (ROA)
-38.41%
RETURN ON ASSETS (ROA) AVG TTM
-84.87%
RETURN ON ASSETS (ROA) AVG 3Y
-95.12%
RETURN ON ASSETS (ROA) AVG 5Y
-75.66%
RETURN ON ASSETS (ROA) AVG 10Y
-74.23%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+54.74%
CURRENT VS 3Y AVG
+59.62%
CURRENT VS 5Y AVG
+49.23%
CURRENT VS 10Y AVG
+48.26%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-42.79%
vs the sector median at left
Allarity Therapeutics, Inc.
Market Cap
$15.91M
Return on Assets (ROA)
-38.41%
TTM Avg
-84.87%
3Y Avg
-95.12%
5Y Avg
-75.66%
Market Cap
$16.22M
Return on Assets (ROA)
-154.34%
TTM Avg
-227.23%
3Y Avg
-240.86%
5Y Avg
-184.63%
Market Cap
$15.30M
Return on Assets (ROA)
-213.77%
TTM Avg
-110.51%
3Y Avg
-93.41%
5Y Avg
-68.22%
Market Cap
$16.54M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
Market Cap
$16.58M
Return on Assets (ROA)
-67.58%
TTM Avg
-90.98%
3Y Avg
-83.38%
5Y Avg
-70.12%
Market Cap
$15.20M
Return on Assets (ROA)
-41.18%
TTM Avg
-60.23%
3Y Avg
-53.11%
5Y Avg
-40.22%
Market Cap
$15.20M
Return on Assets (ROA)
-201.89%
TTM Avg
-113.65%
3Y Avg
-83.24%
5Y Avg
-72.72%
Market Cap
$14.28M
Return on Assets (ROA)
-32.53%
TTM Avg
-31.07%
3Y Avg
-30.77%
5Y Avg
-29.89%
Market Cap
$13.62M
Return on Assets (ROA)
-85.85%
TTM Avg
-102.78%
3Y Avg
-95.22%
5Y Avg
-76.09%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | $15.91M | -38.41% | -84.87% | -95.12% | -75.66% |
| BioCardia, Inc. (BCDA)vs › | $16.22M | -154.34% | -227.23% | -240.86% | -184.63% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -213.77% | -110.51% | -93.41% | -68.22% |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | -116.60% | -66.28% | -71.56% | -63.10% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.58M | -67.58% | -90.98% | -83.38% | -70.12% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.20M | -41.18% | -60.23% | -53.11% | -40.22% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.20M | -201.89% | -113.65% | -83.24% | -72.72% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | -32.53% | -31.07% | -30.77% | -29.89% |
| IN8bio, Inc. (INAB)vs › | $13.62M | -85.85% | -102.78% | -95.22% | -76.09% |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | -123.23% | -153.35% | -205.77% | -166.29% |
ROA
-38.4%
ROE
-348.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -61.51% |
| 2024-12-31 | -108.23% |
| 2023-12-31 | -100.33% |
| 2022-12-31 | -110.41% |
| 2021-12-31 | -53.69% |
| 2020-12-31 | -19.76% |
| 2019-12-31 | -45.28% |
| 2018-12-31 | -5.94% |
| 2017-12-31 | -234.04% |
| 2016-12-31 | -56.34% |
| 2015-12-31 | -21.04% |
| 2014-12-31 | -73.59% |
| 2013-12-31 | -45.10% |
